An AI-powered platform to develop and commercialize immune-driven clinical products tailored to each individual cancer patient.
Immunai is the leading platform to develop and commercialize immune-driven clinical products tailored to each individual patient. The Company has built the world’s largest proprietary, large-scale library of single-cell RNA sequencing (scRNAseq) through data collection from simple blood tests. This world-changing platform utilizes machine-learning algorithms (ML) to build a differentiated cell-atlas that enables a new level of granularity to better understand and manipulate the immune system, improving efficacy of immunotherapy treatments and drug discovery.
Immunai is currently working with two US blue-chip, publicly-traded, pharma companies with 6 more in the pipeline as well as 15 of the world’s top hospitals including Sloan Kettering, UPenn, Stanford, and the Mayo Clinic. The platform assists pharma companies across all stages—from pre-clinical trials to commercialization. They can use Immunai to select patients for clinical trials, determine a drug’s applicability to a specific person, and identify novel targets for drug development. Moreover, Immunai can help clinicians and hospitals to early diagnose cancer and match patients to appropriate treatment regimes.
The company was founded by Noam Solomon (CEO) and Luis Voloch (CTO). Noam, was a postdoctoral researcher at MIT, Harvard, the Weizmann Institute and the Hebrew University, and Luis earned his Ph.D. from MIT and previously served as a machine-learning scientist at MyHeritage.